NorthSea Therapeutics
NorthSea Therapeutics is a Dutch biotech company with the aim of developing novel and innovative therapeutic strategies for non-alcoholic seatohepatitis (NASH) and other metabolic, inflammatory and fibrotic diseases.
In December 2017, the company secured 25 million euros ($29 million) in funding for clinical development of the promising NASH drug, icosabutate.
This funding round, led by Forbion and BGV includes Novo Seeds, the early-stage investment arm of Novo Holdings A/S and New Science Ventures, will help the company to conduct a Phase IIb clinical study in NASH with icosabutate and to develop it to Phase III readiness.
Latest NorthSea Therapeutics News & Features
16 November 2021
8 January 2020
4 September 2019
12 December 2017
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze